Related Experiment Video
Updated: Jul 24, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Renin inhibitors in hypertension
R R Luther1, H N Glassman, R S Boger
1Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064.
Clinical Nephrology
|October 1, 1991
Summary
Renin inhibitors offer a targeted approach to managing hypertension by blocking the renin-angiotensin system (RAS). Clinical studies show these compounds effectively lower blood pressure with good safety profiles.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Biochemistry
Background:
- The renin-angiotensin system (RAS) is crucial for regulating blood pressure and fluid balance.
- Angiotensin converting enzyme inhibitors (ACEIs) are clinically successful for hypertension, prompting research into renin antagonists.
- Renin inhibitors offer greater specificity compared to ACEIs, potentially avoiding side effects related to bradykinin and prostaglandin metabolism.
Purpose of the Study:
- To review the development and clinical evaluation of renin inhibitors as a novel antihypertensive therapy.
- To assess the efficacy, safety, and pharmacokinetic profiles of early-generation renin inhibitors in human studies.
- To explore potential mechanisms and patient factors influencing the blood pressure response to renin inhibition.
Main Methods:
- Review of preclinical and clinical studies on renin inhibitors, including compounds like enalkiren and ditekiren.
- Analysis of dose-response relationships between renin inhibitors, plasma renin activity (PRA), and blood pressure (BP).
- Evaluation of safety, tolerability, and pharmacokinetic data from human trials.
Main Results:
- Renin inhibitors demonstrated dose-dependent reductions in PRA, though not always directly correlated with BP reduction.
- Prolonged and sustained hypotensive effects were observed with certain renin inhibitors (enalkiren, RO 42-5892) without tachyphylaxis.
- Renin inhibitors effectively lowered blood pressure across various baseline renin levels and sodium balance states, with enhanced response in high-renin, sodium-depleted patients.
- Early clinical studies indicated a favorable safety and tolerability profile for renin inhibitors.
Conclusions:
- Renin inhibitors represent a promising class of antihypertensive agents with a specific mechanism of action.
- Further development of more potent and orally bioavailable renin inhibitors may expand their therapeutic role.
- Understanding the dissociation between PRA and BP reduction is key for optimizing renin inhibitor therapy.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...